PARP1 and Miyoshi myopathy: These findings have prompted the translation of these novel therapeutic approaches also in MM, leading to preclinical investigations of the potential role of PARP inhibitors in MM, for example, veliparib in combination with bortezomib as mentioned above [124], and olaparib as monotherapy [126].